Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025

Rhea-AI Summary

Elite Pharmaceuticals (OTCQB:ELTP), a specialty pharmaceutical company focused on niche generic products, will release its Q1 FY2026 financial results on Thursday, August 14, 2025. The company will host a conference call on Friday, August 15, 2025, at 11:30 AM EDT to discuss financial results and provide a business update.

Shareholders can submit general questions by August 13, 2025 (5:00 PM EDT) and financial questions by August 14, 2025 (7:00 PM EDT) to dianne@elitepharma.com. The call will be accessible via 1-800-346-7359 (domestic) or 1-973-528-0008 (international) using conference number 98840. An audio replay will be available on the company's website.

Financials for First Quarter of Fiscal Year 2026 Ended June 30, 2025 will be released on Thursday, August 14, 2025

Northvale, New Jersey--(Newsfile Corp. - August 8, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2026 fiscal year will be released on Thursday, August 14, 2025. Elite's management will host a live conference call on Friday, August 15^th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. Stockholders should submit their questions to the company prior to the call.

Date:	August 15, 2025
Time:	11:30 AM EDT
Dial-in numbers:	1-800-346-7359 (domestic) 1-973-528-0008 (international)
Conference number:	98840
Questions:	dianne@elitepharma.com General questions by 5:00 PM EDT on Wednesday, August 13, 2025 Financial questions by 7:00 PM EDT on Thursday, August 14, 2025
Audio Replay:	https://elite.irpass.com/events_presentations

 

About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261876

FAQ

When will Elite Pharmaceuticals (ELTP) release Q1 2026 earnings?

Elite Pharmaceuticals will release Q1 FY2026 earnings on Thursday, August 14, 2025.

What time is Elite Pharmaceuticals' Q1 2026 earnings call?

The earnings conference call is scheduled for Friday, August 15, 2025, at 11:30 AM EDT.

How can investors submit questions for Elite Pharmaceuticals' Q1 2026 earnings call?

Investors can email questions to dianne@elitepharma.com. General questions are due by August 13, 2025 (5:00 PM EDT) and financial questions by August 14, 2025 (7:00 PM EDT).

What are the dial-in numbers for Elite Pharmaceuticals' Q1 2026 earnings call?

Investors can dial 1-800-346-7359 (domestic) or 1-973-528-0008 (international) using conference number 98840.